+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating clemizole HCl as an additional treatment for children and adults with Lennox-Gastaut syndrome LGS, a severe form of epilepsy. This phase 3 study is randomized, double-blind, and placebo-controlled, aiming to assess both the safety and effectiveness of clemizole HCl when added to current therapies. The study includes an Observational Period, a Double-Blind Period, and an optional Open-Label Extension Period to gather comprehensive data over time. Participants will be randomly assigned to receive either clemizole HCl or a placebo, both given as oral solutions. After completing the Double-Blind Period, eligible participants may choose to continue treatment with clemizole HCl in the Open-Label Extension Period for up to three years. This design helps researchers compare outcomes between the study drug and placebo, and to observe long-term effects of clemizole HCl. During the study, participants will be monitored regularly to measure changes in seizure frequency and severity, using tools like the CMMS-28 scale. Other assessments include global impression scores from clinicians and caregivers, quality of life evaluations, and safety monitoring for adverse events. The primary outcome focuses on seizure changes over 16 weeks, while secondary outcomes look at seizure-free days, overall impact, and safety throughout the trial duration, potentially spanning up to nearly five years.

Age: 2Years - 55YearsAll GendersPhase 3
71 locations
E

Actively Recruiting

This research aims to evaluate the effect of tozorakimab, given in addition to standard care, in adults hospitalized for viral lung infection who require supplemental oxygen. The study focuses on whether this treatment can prevent death or the need for invasive mechanical ventilation IMV or extracorporeal membrane oxygenation ECMO. It is a Phase III, randomized, double-blind, placebo-controlled trial assessing patients with hypoxaemia due to viral lung infection. Participants will be randomly assigned in equal numbers to one of two groups. One group will receive a single intravenous dose of tozorakimab on Day 1, while the other group will receive a matching placebo dose. Both groups will continue to receive standard care alongside the study treatment. The trial is designed to follow patients for up to 60 days to assess various clinical outcomes related to respiratory status and survival. During the study, participants will be monitored for progression to invasive ventilation or death up to 28 days as the primary outcome. Additional assessments include survival at 60 days, time spent outside the intensive care unit, days free from supplemental oxygen, and clinical progression scales. Safety evaluations include monitoring for anti-drug antibodies. The total participation time spans from treatment administration through clinical follow-up up to 60 days.

Age: 18Years +All GendersPhase 3
473 locations
G

Actively Recruiting

Researchers are conducting a Phase 23, multisite, randomized, open-label trial to study first-line treatments for non-small cell lung cancer NSCLC. This trial includes two substudies focusing on different NSCLC histological subtypes due to variations in standard chemotherapy choices. The study aims to evaluate the safety, effectiveness, and behavior of the investigational drug pumitamig combined with chemotherapy and compare it to pembrolizumab plus chemotherapy. Participants in each substudy first join a Phase 2 part where they receive one of two doses of pumitamig plus chemotherapy. In the Phase 3 part, they are randomized to receive either pumitamig plus chemotherapy or pembrolizumab plus chemotherapy. Additional participants in China will be enrolled in a Phase 2 arm to further evaluate a selected dose. Independent committees will review safety data and tumor scans throughout the study. Participants will be involved for up to 64 months, undergoing treatments through intravenous infusions. Their health will be monitored regularly to track side effects, tumor response, progression-free survival, overall survival, and quality of life through questionnaires and scans. Safety assessments include monitoring adverse events and treatment tolerance, with follow-up visits extending up to several years to assess long-term outcomes.

Age: 18Years +All GendersPhase 2Phase 3
366 locations
G

Actively Recruiting

Researchers are evaluating the efficacy and safety of olverembatinib compared to bosutinib in patients with chronic phase chronic myeloid leukemia CML-CP. This phase 3 randomized study includes patients previously treated with at least two tyrosine kinase inhibitors TKIs and also examines olverembatinib in a single-arm group of CML-CP patients with the T315I mutation. The study addresses treatment options for patients with limited effective therapies and includes a crossover option for those meeting failure criteria while on bosutinib. Participants in Part A will be randomly assigned to receive either olverembatinib every other day or bosutinib once daily. Part B involves patients with the T315I mutation receiving olverembatinib alone. Treatment cycles are 28 days, with pharmacokinetic assessments after the first two cycles. Patients may continue treatment and be monitored for up to five years to evaluate long-term outcomes and safety. During the study, participants will undergo assessments including molecular response rates at 24 and 96 weeks, cytogenetic response evaluations at multiple intervals, and monitoring for adverse events. Researchers will also track progression-free and overall survival. Organ function and performance status will be regularly evaluated to ensure safety and treatment adherence throughout the study duration.

Age: 18Years +All GendersPhase 3
163 locations